Showing 13,041 - 13,060 results of 21,342 for search '(( significant ((gender decrease) OR (greatest decrease)) ) OR ( significant decrease decrease ))', query time: 0.64s Refine Results
  1. 13041

    Data Sheet 1_Impact of zero-markup consumable policy and national procurement of coronary stents on hospitalization expenses: an interrupted time series analysis.pdf by Shao-long Wu (1948273)

    Published 2025
    “…The slope change of medical consumables expenses decreased by 600.81 CNY per month after the zero-markup policy, and the immediate effect of the national procurement policy resulted in a decrease of 32,160.81 CNY in median medical consumables expenses. …”
  2. 13042
  3. 13043

    Image 5_Neutrophil proteins as potential biomarkers for a sputum-based tuberculosis screening test.tif by Mark Chambers (1845670)

    Published 2025
    “…</p>Results and discussion<p>Significant increases in all proteins were detectable in sputum from clinic-diagnosed TB participants relative to symptomatic controls. …”
  4. 13044

    Image 1_Neutrophil proteins as potential biomarkers for a sputum-based tuberculosis screening test.tif by Mark Chambers (1845670)

    Published 2025
    “…</p>Results and discussion<p>Significant increases in all proteins were detectable in sputum from clinic-diagnosed TB participants relative to symptomatic controls. …”
  5. 13045

    S1 Data - by Elsabeth Addisu (10803651)

    Published 2024
    “…These results showed a statistically significant full antenatal care utilization gap in rural urban resident women (-0.21807, 95% CI:(-0.27397, -0.16217)). …”
  6. 13046

    Experience-dependent and temporally restricted serotonin signaling and synaptic glomeruli pruning. by Vanessa Kay Miller (19775496)

    Published 2024
    “…Two-way ANOVA with Tukey’s multiple comparison shows a highly significant decrease in the Or42a OSN innervation (<i>n</i> = 28/condition, <i>p</i> = 7.45 × 10<sup>−11</sup>) and increase in serotonin (<i>n</i> = 28/condition, <i>p</i> = 4.10 × 10<sup>−14</sup>). …”
  7. 13047

    Data_Sheet_1_The efficacy and safety of isotonic and hypotonic fluids in intravenous maintenance fluid therapy in term newborns: national multicenter observational “neofluid” study... by Hasan Ozkan (6808268)

    Published 2024
    “…The hypotonic fluid group had a higher incidence of hyponatremia and a clinically meaningful sodium decrease compared to the isotonic fluid group [7.9% vs. 1.2% (OR:6.5, p:0.03)] and [12.2% vs.4.2% (OR:2.9, p = 0.03)].…”
  8. 13048

    DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

    Published 2024
    “…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”
  9. 13049

    5OMV Inhibits HMGB1-Induced Tube Formation in HUVECs. by Wenyue Hou (10203722)

    Published 2025
    “…Mean values showing significant differences between the control group and the HMGB1-treated group are indicated by *(<i>P</i> < 0.05) or ** (<i>P</i> < 0.01). …”
  10. 13050

    Key factors affecting enterprise competitiveness and business efficiency: a case study of tourism enterprises in Vietnam by Phan Thanh Tam (19969603)

    Published 2024
    “…<p>Vietnam’s tourism business has been dramatically affected by the Covid‑19 outbreak, leading to a considerable decrease in the number of tourists visiting the country. …”
  11. 13051

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  12. 13052

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  13. 13053

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  14. 13054

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  15. 13055

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  16. 13056

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  17. 13057

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  18. 13058

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  19. 13059

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
  20. 13060

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”